Clinical Trials
1.2k
Active:14
Completed:632
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:2
Phase 2:20
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (585 trials with phase data)• Click on a phase to view related trials
Not Applicable
525 (89.7%)Phase 3
24 (4.1%)Phase 2
20 (3.4%)Phase 4
12 (2.1%)Early Phase 1
2 (0.3%)Phase 1
2 (0.3%)Early Intervention After Traumatic Exposure in Children and Adolescents
Not Applicable
Not yet recruiting
- Conditions
- Post-traumatic Stress Disorder (PTSD)
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 140
- Registration Number
- NCT07207018
- Locations
- 🇫🇷
CHU Montpellier, Montpellier, Herault, France
Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI
Completed
- Conditions
- NSTEMINSTE-ACS (NSTEMI and UA)NSTEMI - Non-ST-Segment Elevation Myocardial Infarction
- First Posted Date
- 2025-10-02
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 407
- Registration Number
- NCT07204847
- Locations
- 🇫🇷
CHU de Montpellier, Montpellier, France
Effectiveness of Autobiographical Rewriting Workshops on the Socio-Professional Functioning of Patients With Borderline Personality Disorder Undergoing Third-Wave Cognitive and Behavioral Therapy: A Randomized Controlled Trial
Not Applicable
Not yet recruiting
- Conditions
- Borderline Personality DisorderBorderline Personality Disorder (BPD)
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 140
- Registration Number
- NCT07199166
Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia
Active, not recruiting
- Conditions
- Depression - Major Depressive DisorderDepression DisorderSuicide
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 456
- Registration Number
- NCT07199179
- Locations
- 🇫🇷
Chu Montpellier, Montpellier, France
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Not Applicable
Not yet recruiting
- Conditions
- Anti-CD20 TherapyRelapsing-Remitting Multiple Sclerosis (RRMS)
- Interventions
- Drug: Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)Drug: Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 250
- Registration Number
- NCT07189325
- Locations
- 🇫🇷
Neurology Department, Hospital Gui de Chauliac, Montpellier, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 242
- Next
News
No news found